GLPwatch
Papers (9189)
Page 19 of 154, ranked by citation count.
- Post hoc analysis of the Exenatide-PD trial-Factors that predict response.
- Neuroprotective effect of liraglutide in an experimental mouse model of multiple sclerosis: role of AMPK/SIRT1 signaling and NLRP3 inflammasome.
- Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial.
- Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia).
- Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus.
- Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis.
- LEADER 3--lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial.
- Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials.
- What Effects Might Exenatide have on Non-Motor Symptoms in Parkinson's Disease: A Post Hoc Analysis.
- GLP-1 Receptor Agonists: A New Treatment in Parkinson's Disease.
- Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study.
- Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: An updated meta-analysis of randomized controlled trials.
- Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease.
- Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study.
- Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes.
- A phase 3 randomized clinical trial using a once-weekly glucagon-like peptide-1 receptor agonist in adolescents and young adults with hypothalamic obesity.
- GLP-1R as a Target for the Treatment of Diabetic Retinopathy: Friend or Foe?
- Upper and/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists: Incidence and consequences.
- Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-analysis.
- Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States.
- Diabesity: therapeutic options.
- Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials.
- Stable Incretin Mimetics Counter Rapid Deterioration of Bone Quality in Type 1 Diabetes Mellitus.
- Liraglutide prevents and reverses monocrotaline-induced pulmonary arterial hypertension by suppressing ET-1 and enhancing eNOS/sGC/PKG pathways.
- Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes.
- Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes.
- Brain region specific glucagon-like peptide-1 receptors regulate alcohol-induced behaviors in rodents.
- Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects.
- Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial.
- Effects of GLP-1 Receptor Agonists on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus: A 52-Week Clinical Study.
- Impact of acute hyperglycemia on myocardial infarct size, area at risk, and salvage in patients with STEMI and the association with exenatide treatment: results from a randomized study.
- Weight beneficial treatments for type 2 diabetes.
- Liver-derived fibroblast growth factor 21 mediates effects of glucagon-like peptide-1 in attenuating hepatic glucose output.
- Short-term intervention with liraglutide improved eating behavior in obese women with polycystic ovary syndrome.
- Effects of glycaemic management on diabetic kidney disease.
- Evolution of exenatide as a diabetes therapeutic.
- Long acting GLP-1 analog liraglutide ameliorates skeletal muscle atrophy in rodents.
- Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment.
- Expression of the glucagon-like peptide-1 receptor and its role in regulating autophagy in endometrial cancer.
- Efficacy of the glucagon-like peptide-1 agonist exenatide in the treatment of short bowel syndrome.
- Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies.
- Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial.
- Largest single-centre experience of dulaglutide for management of diabetes mellitus in solid organ transplant recipients.
- Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment.
- Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review.
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.
- Injectable hydrogel for sustained protein release by salt-induced association of hyaluronic acid nanogel.
- Options for combination therapy in type 2 diabetes: comparison of the ADA/EASD position statement and AACE/ACE algorithm.
- Coadministration of liraglutide with tacrolimus in kidney transplant recipients: a case series.
- Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis.
- Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program.
- Glucagon-like peptide-1 receptor action in the vasculature.
- Comparison of triple quadrupole and high-resolution TOF-MS for quantification of peptides.
- Liraglutide relieves myocardial damage by promoting autophagy via AMPK-mTOR signaling pathway in zucker diabetic fatty rat.
- Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide.
- Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes.
- Umami receptor activation increases duodenal bicarbonate secretion via glucagon-like peptide-2 release in rats.
- Dipeptidyl peptidase-4 inhibitor improved exercise capacity and mitochondrial biogenesis in mice with heart failure via activation of glucagon-like peptide-1 receptor signalling.
- Chemical Conjugation of Evans Blue Derivative: A Strategy to Develop Long-Acting Therapeutics through Albumin Binding.
- Dynamics of GLP-1R peptide agonist engagement are correlated with kinetics of G protein activation.